MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Enveric Biosciences

< Previous 1 2 3 Next >
News headline image
Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Announces Participation in 2026 BIO International Convention
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences to Participate in a Panel Discussion at Needham’s Virtual Psychedelics Forum
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Announces Withdrawal of Petition Against Its Patent
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Announces Patent Issuance
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Announces Reverse Stock Split
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences to Explore Digital Asset Treasury Opportunities
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
From Enveric Biosciences
Via Business Wire
Tickers ENVB
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story